Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022399 · ClinicalTrials.gov registry record · Phase 2
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00022399 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 73 participants.
The verdict
NCT00022399, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer. PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before surgery to remove the prostate in treating patients who have localized prostate cancer.
Interventions
- DRUG Placebos
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2002-04-25 |
| Est. Completion | 2005-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022399
The ClinicalTrials.gov registry entry for NCT00022399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT00022399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022399 about?
NCT00022399 is a clinical study titled "Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer". RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer. PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before surgery to remove t...
What is the current status of trial NCT00022399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2002-04-25. Estimated completion is 2005-01-31.
What interventions are being tested in trial NCT00022399?
The interventions under investigation include: Placebos (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00022399?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.